SCHEMBL3103044

SCHEMBL3103044

CC(c1cnc(F)c(B(O)O)c1)N1CCN(C(=O)OC(C)(C)C)C[C@H]1C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 13/20 0.41
SMARCA2 P51531 1/20 0.37
SMARCA4 P51532 1/20 0.37
PBRM1 Q86U86 1/20 0.37
HTT P42858 2/20 0.36
ATM Q13315 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP3A5 P20815 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
USP30 Q70CQ3 1/20 0.35
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCND3 P30281 1/20 0.35
CDK6 Q00534 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3101945 1.00 GPR119 (0.41) GPR119SMARCA2SMARCA4PBRM1HTT
SCHEMBL3101956 1.00 GPR119 (0.41) GPR119SMARCA2SMARCA4PBRM1HTT
SCHEMBL3118258 1.00 GPR119 (0.41) GPR119SMARCA2SMARCA4PBRM1HTT
SCHEMBL3103063 1.00 GPR119 (0.41) GPR119SMARCA2SMARCA4PBRM1HTT
SCHEMBL3103594 1.00 GPR119 (0.41) GPR119SMARCA2SMARCA4PBRM1HTT
SCHEMBL116522 0.83 CYP3A4 (0.46) GPR119HTTATMCYP3A4CYP3A5
SCHEMBL116523 0.83 CYP3A4 (0.46) GPR119HTTATMCYP3A4CYP3A5
SCHEMBL116109 0.83 GPR119 (0.43) GPR119SMARCA2SMARCA4PBRM1HTT
SCHEMBL3108477 0.83 GPR119 (0.43) GPR119SMARCA2SMARCA4PBRM1HTT
SCHEMBL3103252 0.83 GPR119 (0.43) GPR119SMARCA2SMARCA4PBRM1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424859-B1 INHIBITORS OF PI3 KINASE AND / OR MTOR AMGEN INC (US) 2015-04-08 EP disclosed
US-8772480-B2 Inhibitors of PI3 kinase and/or mTOR AMGEN INC. (US) 2014-07-08 US disclosed
US-20130079303-A1 Inhibitors of PI3 Kinase and/or mTOR AMGEN INC. (US) 2013-03-28 US disclosed
US-8362241-B2 Inhibitors of PI3 kinase and/or mTOR AMGEN INC. (US) 2013-01-29 US disclosed
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR AMGEN INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR MTOR, PIK3CA, PIK3CD GPR119 618/4885SMARCA2 1376/4885SMARCA4 1090/4885
US-20130079303-A1 Inhibitors of PI3 Kinase and/or mTOR MTOR, PIK3CA, PIK3CD GPR119 618/4885SMARCA2 1376/4885SMARCA4 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.